2 Outstanding Dividend Stocks to Buy and Hold for a Decade

Eli Lilly reported Q2 revenue growth of 48% year over year to $23.0 billion and adjusted EPS growth of 33% to $8.38, driven by Mounjaro and Zepbound; its dividend has more than doubled over five years despite a 0.6% forward yield. Merck's Q2 sales rose 5% to $16.6 billion, while Keytruda's U.S. patent expiry in 2028 remains a major risk; Keytruda Qlex, Winrevair, Capvaxive and pipeline assets are positioned to offset the eventual loss of exclusivity. Merck offers a 2.3% forward dividend yield and has increased payouts by nearly 90% over the past decade.

Analysis

LLY’s investment case is increasingly a duration-versus-execution trade, not a dividend story. The market is likely underwriting sustained GLP-1 volume growth and premium pricing well beyond the next 12-18 months; incremental label breadth and next-generation assets protect that narrative, but also raise the hurdle for manufacturing scale, payer access, and trial readouts. The more relevant second-order beneficiary is the obesity-treatment ecosystem—specialty pharmacies, device manufacturers, and selected diagnostics—but LLY’s valuation leaves little tolerance for a single quarter of supply normalization or realized-price pressure.

MRK has a more asymmetric setup: its multiple embeds considerable concern around the 2028 oncology franchise erosion, while the key question is whether formulation conversion can preserve enough patient and physician loyalty before biosimilar competition arrives. Subcutaneous adoption could improve site-of-care economics and create switching friction, but it does not eliminate payer incentives to favor lower-cost alternatives once exclusivity ends. Winrevair execution, vaccine uptake, and business-development activity are the nearer-term variables that can narrow the perceived replacement gap over the next 12-24 months.

Consensus likely overstates the defensiveness of LLY and understates MRK’s timing risk. LLY can remain operationally excellent while its shares de-rate if growth decelerates from extraordinary to merely strong; MRK can re-rate on evidence of non-Keytruda growth, but its upside is capped unless management quantifies durable post-2028 cash flows. Neither NFLX nor NVDA has a fundamental read-through from this item.

Key Decisions for Investors

• Prefer a 6-12 month pair trade: long MRK / short LLY in equal dollar beta-adjusted amounts. The thesis is relative multiple normalization as MRK’s replacement-franchise evidence accumulates and LLY faces tougher GLP-1 growth comparisons; reassess if LLY raises full-year revenue guidance materially or MRK reduces medium-term revenue/cash-flow expectations.
• For long-only healthcare exposure, retain LLY but do not add into strength ahead of the next earnings release; add only after independently verified evidence that volume growth is not being purchased through lower net pricing. A missed revenue-growth expectation or gross-margin compression is the key near-term downside trigger.
• Buy MRK opportunistically on oncology-patent-cliff-driven weakness over the next 1-3 months, targeting a 12-18 month hold. Position sizing should remain moderate until management discloses conversion rates for the subcutaneous franchise and provides clearer contribution guidance for newer products.
• Set a 2027 watch alert for MRK: accelerated biosimilar filings, restrictive payer coverage, or weak conversion persistence would invalidate the post-exclusivity defense and warrant reducing exposure before the patent cliff becomes the dominant valuation driver.